For STEM students considering career paths, the PA, NJ, & DE region is recognized as one of the leading biotechnology & ...

The company's stock value has tanked before - it was once worth $1 billion.

David Reese believes that AI’s greatest impact will come from improving the thousands of human-led decisions. If Reese, the ...

This experimental pill helped people lose about 16% of their body weight after about a year of treatment ...

This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, will host a ...

After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes shape, said Santé Ventures’ Omar Khalil.

Kraig Biocraft Laboratories (OTCQB:KBLB) deployed one million genetically engineered silkworm eggs across multiple ...

A global pharmaceutical company is moving into Center City next year — and it could be a “game-changing” development for Philly’s biotech scene, a leader in the space says. “We see it as a ...

George is a professor of genetics at Harvard Medical School and professor of health sciences and technology at Harvard and MIT. He is a prolific researcher studying genetic sequencing, genome editing, ...